

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 September 2022 (01.09.2022)



(10) International Publication Number
WO 2022/180203 A1

(51) International Patent Classification:
A61K 35/76 (2015.01) *C12P 35/00* (2006.01)
C12N 7/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2022/054766

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
25 February 2022 (25.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21159746.3 26 February 2021 (26.02.2021) EP

(71) Applicant: **ABALOS THERAPEUTICS GMBH**
[DE/DE]; Merowingerplatz 1A, 40225 Duesseldorf (DE).

(72) Inventors: **VOLLMER, Joerg**; c/o Abalos Therapeutics GmbH, Merowingerplatz 1 A, 40225 Duesseldorf (DE). **KOSTKA, Marcus**; c/o Abalos Therapeutics GmbH, Merowingerplatz 1 A, 40225 Duesseldorf (DE). **LANG, Philipp**; c/o Universitaetsklinikum Duesseldorf, Institut für molekulare Medizin II, Universitaetsstrasse 1, 40225 Duesseldorf (DE). **XU, Haifeng**; c/o Universitaetsklinikum Duesseldorf, Institut für molekulare Medizin II, Universitaetsstrasse 1, 40225 Duesseldorf (DE).

(74) Agent: **SCHIWECK, Wolfram** et al.; Schiweck Weinzierl Koch, Patentanwälte, Ganghoferstrasse 68b, 80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: NEW VIRUS PARTICLES FOR THERAPEUTIC PURPOSES

(57) Abstract: The invention relates to a virus particle comprising a lymphocytic choriomeningitis virus (LCMV) S segment and an LCMV L segment, wherein the S segment comprises an open reading frame encoding a glycoprotein derived from LCMV strain WE, and wherein the L segment comprises an open reading frame encoding an L protein derived from LCMV strain Clone13. The invention also relates to related host cells, methods of producing such virus particles, pharmaceutical compositions comprising such virus particles, and medical uses of such virus particles.

WO 2022/180203 A1